•The MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint of the annualized rate of decline in forced vital capacity (FVC).
•Axatilimab was well tolerated with a safety profile consistent with previous clinical studies and no new safety signals identified.
•Digital asset investment manager 3iQ has received in-principle approval from the Financial Services Regulatory Authority (FSRA) in Abu Dhabi Global Market.
